DiaKine Therapeutics, Inc.
Richmond
Virginia
United States
16 articles about DiaKine Therapeutics, Inc.
-
Islet Sciences Announces DiaKine Therapeutics, Inc.' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
3/30/2012
-
Islet Sciences Announces Closing of Islet Sciences Acquisition
3/23/2012
-
Islet Sciences Enters Into Agreement to Acquire DiaKine Therapeutics, Inc.
2/29/2012
-
DiaKine Therapeutics, Inc. Named a Top Innovator by youngStartup Ventures
12/8/2009
-
DiaKine Therapeutics, Inc. Diabetes Immune Modulator Drug Set for Human Clinical Trial
5/12/2009
-
DiaKine Therapeutics, Inc. Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study
1/22/2009
-
DiaKine Therapeutics, Inc.'s Lead Compound in Phase 2 Clinical Trial
10/14/2008
-
DiaKine Therapeutics, Inc. and Kinexum Metabolics, Inc. to Develop Novel Combination Treatment to Type 1 Diabetes
5/6/2008
-
DiaKine Therapeutics, Inc. Release: Combination Drug Therapy May Hold the Key to Reversing Type 1 Diabetes
4/8/2008
-
DiaKine Therapeutics, Inc. to Be Awarded Patent for Restoring Insulin Producing Cell Function in Diabetics
4/1/2008
-
Pioneer in Successful Islet Cell Transplants Named to DiaKine Therapeutics, Inc.' Scientific Advisory Board
2/12/2008
-
National Institutes of Health (NIH) to Sponsor Preclinical Study of DiaKine Therapeutics, Inc. Diabetes Drug
10/9/2007
-
Dr. Alexander Fleming Named to DiaKine Therapeutics, Inc.' Scientific Advisory Board
5/15/2007
-
DiaKine Therapeutics, Inc. And AdPharma To Develop Diabetes Inhibiting Drugs
1/31/2007
-
DiaKine Therapeutics, Inc. And Mediatech, Inc. To Market Immune Modulating Media Designed To Improve Islet Cell Transplants
1/10/2007
-
Tech Council of Maryland Release: Area Life Science Companies Chosen To Make Presentations For Venture Funding At 2005 Mid-Atlantic Bio
10/12/2005